Skip to main content
Log in

Churg-Strauss syndrome successfully treated with rituximab

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript


Churg-Strauss syndrome (CSS) is characterized by small-vessel vasculitis, extravascular granulomatous inflammation, and massive eosinophilia in tissues and blood, and is often accompanied by a history of preclinical asthma and/or allergic rhinitis lasting several years before the syndrome develops its full clinical picture. Corticosteroids, often in combination with cytotoxic agents, comprise standard therapy; however, a number of patients appear to be resistant to treatment and there is a need for more effective regimens. B cell depletion may be an effective treatment option for CSS. Here, we describe two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.


  1. Calabrese LH, Duna G (2005) Antineutrophil cytoplasmic antibody-associated vasculitis. In: Harris ED Jr et al (eds) Kelly’s textbook of rheumatology, 7th edn. Elsevier Saunders, Philadelphia, pp 1357–1378

    Google Scholar 

  2. Arkfeld DG (2008) The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 28:205–215

    Article  CAS  PubMed  Google Scholar 

  3. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D et al (2008) Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 47:1104–1105

    Article  CAS  PubMed  Google Scholar 

  4. Koukoulaki M, Smith KGC, Jayne DRW (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65:557–559

    Article  CAS  PubMed  Google Scholar 

  5. Kaushik VV, Reddy HV, Bucknall RC (2006) Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 65:1116–1117

    Article  CAS  PubMed  Google Scholar 

  6. Smith KGC, Jones RB, Burns SM, Jayne DRW (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthritis Rheum 54:2970–2982

    Article  CAS  PubMed  Google Scholar 

  7. Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol 33(Suppl 77):24–28

    Google Scholar 

  8. Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL et al (2008) The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case crossover study. Thorax 63:677–682

    Article  CAS  PubMed  Google Scholar 

  9. Girszyn N, Amiot N, Lahaxe L, Cuvelier A, Courville P, Marie I (2008) Churg-Strauss syndrome associated with montelukast therapy. Q J Med 101:669–671

    CAS  Google Scholar 

  10. Gøransson LG, Brodin C, Øgreid P, Janssen EAM, Romundstad PR, Vatten L et al (2008) Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality. Scand J Rheumatol 37:130–134

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Roald Omdal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dønvik, K.K., Omdal, R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 31, 89–91 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: